October 31, 2018
Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Media
October 31, 2018
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
October 26, 2018
Targovax ASA: Announcement of Third Quarter 2018 Financial Results
October 26, 2018
Interim Report July – September 2018
October 26, 2018
GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa
October 26, 2018
Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma
October 25, 2018
Oncopeptides to host a Capital Markets Day in New York on December 14th
October 25, 2018
Interim Report Q3 2018
October 25, 2018
Nordic Nanovector’s Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma
October 24, 2018
Save the date: Orexo to host Capital Markets Day on Dec. 6 with the US president´s former advisor as key note speaker
